Thermo Fisher Scientific has obtained FDA approval for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS®, a tyrosine kinase inhibitor targeting HER2-mutated non-small cell lung cancer. The test detects activating HER2 tyrosine kinase domain mutations, enabling identification of patients eligible for the new treatment. This approval supports precision oncology efforts in lung cancer, facilitating more informed therapeutic decisions and advancing targeted treatment strategies.